Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Review At US FDA: Record Month Completes Approval Volume Recovery

Executive Summary

With 96 full ANDA approvals and 30 tentative approvals, July was the most productive month since GDUFA launched.

You may also be interested in...



US FDA's Generics Program Reaches 'Steady State' Milestone

OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.

US FDA's Generics Program Reaches 'Steady State' Milestone

OGD Director Uhl says program is now in balance between the number of submissions and agency review actions.

Gottlieb's 2018 Generic Drug Approval Goal May Be In Doubt

Thanks in large part to new elemental impurities requirements, ANDA approvals are behind the pace needed to beat 2017’s record.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS123675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel